Overview

A Phase 2a Study to Evaluate Viral Kinetics and Safety of Telaprevir in Participants With Genotype 2 or 3 Hepatitis C Infection

Status:
Completed

Trial end date:
2009-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the effect of telaprevir on early hepatitis (inflammation of the liver) C virus (HCV) viral kinetics in treatment-naive participants who are chronically (lasting a long time) infected with genotype 2 or 3 HCV.

Phase:

Phase 2

Details

Lead Sponsor:

Tibotec BVBA

Treatments:

Interferon alpha-2
Interferon-alpha
Peginterferon alfa-2a
Ribavirin